Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.
- DOI
- 10.1136/bmjph-2025-004789
- Published
- 2026
- Container
- BMJ public health
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjph-2025-004789,
title = {Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.},
author = {Gao X and Li R and Xie F and Yu M and Wang YL and Zhang XL and Wang PM and Xiao FY and Lin YS and Gu XF and Zhao K and Zhang YZ and Butt T and Yao L and Li X and Guo WD},
year = {2026},
journal = {BMJ public health},
doi = {10.1136/bmjph-2025-004789},
url = {https://doi.org/10.1136/bmjph-2025-004789}
}RIS
TY - JOUR TI - Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study. AU - Gao X AU - Li R AU - Xie F AU - Yu M AU - Wang YL AU - Zhang XL AU - Wang PM AU - Xiao FY AU - Lin YS AU - Gu XF AU - Zhao K AU - Zhang YZ AU - Butt T AU - Yao L AU - Li X AU - Guo WD PY - 2026 JO - BMJ public health DO - 10.1136/bmjph-2025-004789 UR - https://doi.org/10.1136/bmjph-2025-004789 ER -
APA
X, G., R, L., F, X., M, Y., YL, W., XL, Z., PM, W., FY, X., YS, L., XF, G., K, Z., YZ, Z., T, B., L, Y., X, L., & WD, G. (2026). Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.. BMJ public health. https://doi.org/10.1136/bmjph-2025-004789
Source records
- pubmed · retrieved 2026-09-25T14:59:29.660Z